Evidence map›Paper›PMID 32417490›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2020

T Cell Clonal Dynamics Determined by High-Resolution TCR-β Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation.

Mark Leick, Rachel M Gittelman, Erik Yusko, Catherine Sanders, Harlan Robins, Zachariah DeFilipp, Sarah Nikiforow, Jerome Ritz, Yi-Bin Chen

Open access · hybridAbstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Healthy-like CD4International journal of molecular sciences · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mark LeickBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
Rachel M GittelmanAdaptive Biotechnologies, Seattle, Washington.
Erik YuskoAdaptive Biotechnologies, Seattle, Washington.
Catherine SandersAdaptive Biotechnologies, Seattle, Washington.
Harlan RobinsAdaptive Biotechnologies, Seattle, Washington.
Zachariah DeFilippBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
Sarah NikiforowDivision of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jerome RitzDivision of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.
Yi-Bin ChenBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: ychen6@partners.org.
Adaptive Biotechnologies (United States) · USMassachusetts General Hospital · USDana-Farber Cancer Institute · US

Funding

Training Program in Cancer Biology and TherapeuticsT32CA071345 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber, Lecia V. Sequist · 1997 to 2026
$10.6M
NCI NIH HHS T32 CA071345
6 · The paper itself

Abstract

Delayed reconstitution of the immune system is a long-recognized complication after allogeneic hematopoietic cell transplantation (HCT). Specifically, loss of T cell diversity has been thought to contribute to infectious complications, graft-versus-host disease (GVHD), and disease relapse. We performed serial high-resolution next-generation sequencing of T cell receptor (TCR)-β in 99 related or unrelated donor (57 unrelated, 42 related) allogeneic HCT recipients (55 with reduced-intensity conditioning, 44 with myeloablative conditioning) during the first 3 months after HCT using the immunoSEQ Assay. We measured T cell fraction, clonality (1- Peilou's evenness) and Daley-Smith richness from recipient samples at multiple time points. In agreement with previous studies, we found that although absolute T cell numbers recover relatively quickly after HCT, T cell repertoire diversity remains diminished. Restricted diversity was associated with conditioning intensity, use of antithymocyte globulin, and donor type. Increased number of expanded clones compared to donor T cell clones at day +30 was associated with the incidence of acute GVHD (hazard ratio [HR], 1.11; P = .00005). Even after exclusion of the 12 patients who developed acute GVHD before day +30, the association between acute GVHD and increased clonal expansion at day +30 remained (HR, 1.098; P = .041), indicating that increased clonal T cell expansion preceded the development of acute GVHD. Our results highlight T cell clonal expansion as a potential novel biomarker for acute GVHD that warrants further study.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansT-LymphocytesTransplantation ConditioningUnrelated DonorsT cell clonalityT cell clonotypingT cell receptor sequencingTCR-β sequencing

Identifiers

PMID32417490
PMCPMC8279830
OpenAlexW3025664890

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.